Table 2 Some oncolytic virus products in clinical trials for liver cancer
From: Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer
Type of OVs | Product name | Pharmaceuticals company | Route of administration | Clinical phase |
|---|---|---|---|---|
AdV | OBP-301 | Oncolys Inc | Intratumoral | II |
AdV | Onyx-015 | Onyx Inc | Intratumoral | II |
AdV | SynOV1.1 | Beijing SyngenTech | Intratumoral | I |
Poxvirus | Pexa-vec | Jennerex Inc | Intratumoral, intravenous | III |
Poxvirus | JX594 | Jennerex Inc | Intratumoral | II |
HSV | SEPREHVIR | Sorrento Inc | Intratumoral | II |
HSV | T-vec | Amgen | Intratumoral | II |
HSV | MVR-T3011 | Invbio | Intratumoral | II |
HSV | VG161 | Virogin Biotech | Intratumoral | II |
HSV | RP2/3 | Replimune | Intratumoral | I |